Los Angeles Capital Management & Equity Research Inc. Has $142,039,000 Position in Merck & Co. (MRK)
Los Angeles Capital Management & Equity Research Inc. raised its position in shares of Merck & Co. (NYSE:MRK) by 7.7% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,465,531 shares of the company’s stock after buying an additional 177,087 shares during the period. Merck & Co. accounts for 1.2% of Los Angeles Capital Management & Equity Research Inc.’s holdings, making the stock its 7th largest position. Los Angeles Capital Management & Equity Research Inc. owned about 0.09% of Merck & Co. worth $142,039,000 at the end of the most recent reporting period.
A number of other large investors have also added to or reduced their stakes in MRK. Emerald Acquisition Ltd. purchased a new position in shares of Merck & Co. during the second quarter worth $274,347,000. Orbis Allan Gray Ltd purchased a new position in shares of Merck & Co. during the first quarter worth $239,761,000. Bank of Montreal Can purchased a new position in shares of Merck & Co. during the second quarter worth $250,542,000. Boston Partners boosted its position in shares of Merck & Co. by 23.8% in the second quarter. Boston Partners now owns 19,034,299 shares of the company’s stock worth $1,096,566,000 after buying an additional 3,655,639 shares in the last quarter. Finally, NN Investment Partners Holdings N.V. purchased a new position in shares of Merck & Co. during the first quarter worth $174,068,000. 72.93% of the stock is owned by institutional investors.
Merck & Co. (NYSE:MRK) traded up 0.18% during trading on Friday, hitting $62.77. The stock had a trading volume of 10,775,249 shares. Merck & Co. has a 12-month low of $47.97 and a 12-month high of $64.00. The company has a 50 day moving average of $62.66 and a 200-day moving average of $58.40. The company has a market cap of $173.57 billion, a P/E ratio of 34.43 and a beta of 0.68.
Merck & Co. (NYSE:MRK) last announced its earnings results on Friday, July 29th. The company reported $0.93 EPS for the quarter, beating the consensus estimate of $0.91 by $0.02. Merck & Co. had a return on equity of 23.41% and a net margin of 13.01%. The business earned $9.84 billion during the quarter, compared to the consensus estimate of $9.79 billion. During the same period in the prior year, the business posted $0.86 earnings per share. Merck & Co.’s revenue was up .6% compared to the same quarter last year. On average, equities analysts predict that Merck & Co. will post $3.75 EPS for the current year.
The business also recently announced a quarterly dividend, which was paid on Friday, October 7th. Stockholders of record on Thursday, September 15th were issued a dividend of $0.46 per share. This represents a $1.84 annualized dividend and a dividend yield of 2.93%. The ex-dividend date was Tuesday, September 13th. Merck & Co.’s dividend payout ratio is 101.10%.
MRK has been the subject of a number of research analyst reports. Berenberg Bank restated a “hold” rating and issued a $62.00 price target on shares of Merck & Co. in a research report on Sunday, September 11th. Argus restated a “buy” rating and issued a $65.00 price target on shares of Merck & Co. in a research report on Wednesday, September 14th. Jefferies Group restated a “hold” rating and issued a $56.00 price target (down previously from $57.00) on shares of Merck & Co. in a research report on Monday, September 12th. Credit Suisse Group AG upgraded Merck & Co. from a “neutral” rating to an “outperform” rating and raised their price target for the company from $62.00 to $73.00 in a research report on Sunday, August 7th. Finally, Barclays PLC raised their price target on Merck & Co. from $66.00 to $72.00 and gave the company an “overweight” rating in a research report on Friday, September 9th. One analyst has rated the stock with a sell rating, twelve have assigned a hold rating and nine have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of €63.20 ($70.23).
In other news, Chairman Kenneth C. Frazier sold 392,000 shares of the company’s stock in a transaction on Friday, August 5th. The stock was sold at an average price of €61.81 ($68.68), for a total transaction of €24,229,520.00 ($26,921,688.89). Following the completion of the sale, the chairman now directly owns 760,877 shares of the company’s stock, valued at €47,029,807.37 ($52,255,341.52). The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Clark Golestani sold 3,000 shares of the company’s stock in a transaction on Wednesday, August 10th. The shares were sold at an average price of €63.03 ($70.03), for a total value of €189,090.00 ($210,100.00). The disclosure for this sale can be found here. Insiders own 0.05% of the company’s stock.
About Merck & Co.
Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products, which it markets directly and through its joint ventures. It operates through one segment, Pharmaceutical. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.
Receive News & Ratings for Merck & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. and related companies with MarketBeat.com's FREE daily email newsletter.